Corevitas Multiple Sclerosis (MS) Registry

Multiple Sclerosis Clinical Trial

Official title:

CorEvitas Multiple Sclerosis (MS) Registry

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT03291756
• Other study ID #: CorEvitas-MS-700
• Status: Enrolling by invitation
• Start date: August 10, 2017
• Est. completion date: December 2100

Study information

• Verified date: November 2022
• Source: CorEvitas
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for MS in a cohort of patients cared for by neurologists across North America. Secondary objectives include analyzing the epidemiology and natural history of the disease, its comorbidities, and current treatment practices.

Description:

The objective of the CorEvitas Multiple Sclerosis (MS) Registry is to create a national cohort of patients with MS. Data collected will be used to better characterize the natural history of the disease and to extensively evaluate the effectiveness and safety of medications approved for the treatment of MS. This will be done through the standardized collection of validated patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO), the prevalence and incidence of comorbidities and adverse events, medication utilization patterns and patient productivity measures.

The design is a prospective, non-interventional, observational registry for patients with MS under the care of a licensed neurologist. Longitudinal follow-up data is collected from both patients and their treating neurologist (also known as "Providers" for a CorEvitas registry study) every 6 months (+/- 30 days) during routine clinical encounters using CorEvitas registry forms. These forms collect data on patient demographics, disease duration, medical history (including all prior and current treatments for MS), smoking status, alcohol use, disease activity and severity, pain, as well as other clinician- and patient-reported outcomes, comorbidities and adverse events, infections, hospitalizations, and other targeted safety outcomes. After the enrollment visit, MS patients and physicians will complete the follow-up questionnaires during regularly scheduled clinical encounters. The goal is to collect data from patients and providers at six month intervals. Adverse events may be volunteered spontaneously by the subject, or be discovered as a result of general questioning by the Investigator. During all CorEvitas related visits with the Investigator, subjects will be questioned regarding the occurrence of adverse events.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 1000
• Est. completion date: December 2100
• Est. primary completion date: December 2100
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Has a diagnosis of MS at the time of enrollment.

2. Age 18 years or older at the time of enrollment.

3. Willing to provide Personal Information.

4. Initiating (prescribed or starting) an Eligible Medication for the treatment of MS at the enrollment visit.

Exclusion Criteria:

1) Is participating or planning to participate in a double-blind randomized trial for an MS drug. Note: Concurrent participation in another observational registry or open-label Phase 3b/4 trial is allowed.

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

Locations

Country	Name	City	State
United States	Corrona, LLC	Waltham	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
CorEvitas

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with adverse events (AEs) or serious adverse events (SAEs).	Targeted events include malignancy, anaphylaxis, cardiovascular disease, serious infection, autoimmune disease, MS Relapse, hepatic events, and general serious adverse events.; An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.	Time Frame: A minimum of 10 years from last patient enrolled
Secondary	Patient reported: Patient Clinical Global Impression (PCGI) Scale		Time Frame: every 6 months for 10 years
Secondary	Disease burden: Relapse Information		Time Frame: every 6 months for 10 years
Secondary	Percentage of patients with history of comorbidities		Time Frame: at registry enrollment
Secondary	Physician reported: Nine-Hole Peg Test (9-HPT)		Time Frame: every 6 months for 10 years
Secondary	Physician reported: Symbol Digit Modalities Test (SMDT)		Time Frame: every 6 months for 10 years
Secondary	Patient reported: Patient reported: Work productivity and Activity Impairment (WPAI)		Time Frame: every 6 months for 10 years
Secondary	Patient reported: Patient reported :MS Quality of Life, MSIS-29		Time Frame: every 6 months for 10 years
Secondary	Patient reported: MS Disability Score29		Time Frame: every 6 months for 10 years

External Links

•   CorEvitas home page